Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
This Therapy Improves Survival in Testicular DLBCL
Leuk Lymphoma; ePub 2017 May 9; Ho, Dabaja, et al
Testicular radiation is linked with improved survival in patients with testicular diffuse large B-cell lymphoma (DLBCL), according to a study involving 120 individuals.
Participants had Stage I-IV testicular DLBCL and were treated between 1964 and 2015. Investigators looked at how testicular radiation and prophylactic central nervous system (CNS) therapies each impacted overall, progression free, testicular relapse free, and CNS relapse free survival. Among the results:
- 7 in every 10 received radiation therapy.
- 53% received anthracyclines and rituximab.
- 6 in every 10 received CNS prophylaxis.
- Univariate analysis showed that radiation therapy was linked with improved testicular relapse free and progression free survival.
- On multivariate analysis, radiation was significantly linked with improved overall and progression free survival.
- The progression free survival benefit persisted in patients receiving anthracyclines and rituximab.
- CNS prophylaxis was not significant on multivariate analysis.
Ho J, Dabaja B, Milgrom S, et al. Radiation therapy improves survival in patients with testicular diffuse large B-cell lymphoma. [Published online ahead of print May 9, 2017]. Leuk Lymphoma. doi:10.1080/10428194.2017.1312381.